Sanofi (NASDAQ:SNY) Stake Boosted by Trivant Custom Portfolio Group LLC

Trivant Custom Portfolio Group LLC raised its position in shares of Sanofi (NASDAQ:SNY) by 47.5% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 17,680 shares of the company’s stock after buying an additional 5,693 shares during the quarter. Trivant Custom Portfolio Group LLC’s holdings in Sanofi were worth $981,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in the company. Farther Finance Advisors LLC lifted its position in Sanofi by 66.2% in the 1st quarter. Farther Finance Advisors LLC now owns 6,215 shares of the company’s stock worth $338,000 after buying an additional 2,476 shares in the last quarter. Allspring Global Investments Holdings LLC increased its stake in shares of Sanofi by 128.0% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 115,330 shares of the company’s stock worth $5,558,000 after acquiring an additional 64,747 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Sanofi by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 257,655 shares of the company’s stock worth $12,427,000 after acquiring an additional 2,917 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Sanofi by 8.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 151,945 shares of the company’s stock worth $7,328,000 after acquiring an additional 12,440 shares in the last quarter. Finally, IFP Advisors Inc boosted its position in Sanofi by 17.2% during the fourth quarter. IFP Advisors Inc now owns 2,132 shares of the company’s stock valued at $103,000 after purchasing an additional 313 shares during the last quarter. 14.04% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. The Goldman Sachs Group began coverage on Sanofi in a research report on Friday, March 21st. They issued a “neutral” rating and a $65.00 target price on the stock. Morgan Stanley set a $56.00 price objective on Sanofi in a report on Monday, June 2nd. BNP Paribas began coverage on shares of Sanofi in a research report on Tuesday, April 15th. They set an “outperform” rating and a $65.00 price objective on the stock. Guggenheim reissued a “buy” rating on shares of Sanofi in a research report on Tuesday, June 3rd. Finally, Hsbc Global Res upgraded shares of Sanofi to a “strong-buy” rating in a report on Monday, April 28th. Three analysts have rated the stock with a hold rating, three have given a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, Sanofi currently has an average rating of “Buy” and an average price target of $61.50.

Sanofi Stock Down 1.2%

Shares of SNY stock opened at $47.62 on Thursday. The stock’s 50 day simple moving average is $51.35 and its 200 day simple moving average is $52.01. Sanofi has a twelve month low of $45.80 and a twelve month high of $60.12. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.69 and a current ratio of 1.37. The company has a market capitalization of $116.79 billion, a price-to-earnings ratio of 17.01, a PEG ratio of 0.97 and a beta of 0.50.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, April 24th. The company reported $0.94 EPS for the quarter, beating analysts’ consensus estimates of $0.90 by $0.04. Sanofi had a net margin of 14.56% and a return on equity of 17.15%. The company had revenue of $10.41 billion for the quarter, compared to analyst estimates of $9.79 billion. During the same quarter last year, the firm posted $1.78 earnings per share. The company’s quarterly revenue was down 11.0% compared to the same quarter last year. As a group, research analysts predict that Sanofi will post 4.36 EPS for the current year.

Sanofi Increases Dividend

The company also recently announced an annual dividend, which was paid on Thursday, June 12th. Investors of record on Friday, May 9th were issued a $2.0369 dividend. This represents a yield of 3.1%. The ex-dividend date was Friday, May 9th. This is an increase from Sanofi’s previous annual dividend of $1.48. Sanofi’s dividend payout ratio (DPR) is 57.14%.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.